Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Grant revenue by Quarter
Grant revenue — Total (BARDA, DARPA, CEPI & Gates Foundation) ($M) ($M)
Moderna Grant revenue: $2M in Q2 2026, down 60.0% from a year earlier.
Latest, Q2 2026
2
Period ended Jun 30, 2026
Change on a year earlier
-60.0%
5 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
28
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Note 3.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Grant revenue — Total (BARDA, DARPA, CEPI & Gates Foundation) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2 | -60.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 0 | -100.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 2 | -80.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 14 | +100.0% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 5 | -75.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 1 | – | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 10 | -600.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 7 | -84.1% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 20 | -28.6% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | -100.0% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | -2 | -96.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 44 | -69.4% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 28 | -84.7% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 24 | -81.0% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | -65 | -124.8% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 144 | +2.9% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 183 | +31.7% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 126 | -35.1% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 262 | -23.4% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 140 | -3.4% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 139 | +265.8% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 194 | +4,750.0% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 342 | +10,263.6% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2020 | Sep 30, 2020 | 145 | +3,818.9% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 38 | +1,166.7% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 4 | +110.5% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 3.30 | +26.9% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 3.70 | -27.5% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 3 | 0.0% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 1.90 | +18.7% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 2.60 | – | Form 10-K (filed 2021-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | 5.10 | – | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 3 | – | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2018 | Mar 31, 2018 | 1.60 | – | Form 10-Q (filed 2019-05-09) ↗ |
Breakdown
What makes up grant revenue
Cite this data
StockData. (2026). Moderna Grant revenue ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-grant
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.